[Outpatient therapy of epilepsy].
D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D001463:Barbiturates / Q000627:therapeutic use*; D003864:Depression, Chemical; D003875:Drug Eruptions; D004342:Drug Hypersensitivity / Q000209:etiology; D004828:Epilepsies, Partial / Q000188:drug therapy; D004827:Epilepsy / Q000188:drug therapy*; D004832:Epilepsy, Absence / Q000188:drug therapy; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy; D004830:Epilepsy, Tonic-Clonic / Q000188:drug therapy; D005013:Ethosuximide / Q000627:therapeutic use*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D010044:Outpatient Clinics, Hospital; D010672:Phenytoin / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000627:therapeutic use*; D012890:Sleep / Q000187:drug effects; D014839:Vomiting / Q000139:chemically induced
D000927:Anticonvulsants; D001463:Barbiturates; D011743:Pyrimidines; D011744:Pyrimidinones; D005013:Ethosuximide; D010672:Phenytoin
Zu Fragen der ambulanten Epilepsiebehandlung.